Pricing Log in Create free account

Immunocore Holdings PLC Sponsored ADR (IMCR) vs Intellia Therapeutics, Inc. (NTLA)

Immunocore Holdings PLC Sponsored ADR and Intellia Therapeutics, Inc. are both Biotechnology companies. Immunocore Holdings PLC Sponsored ADR and Intellia Therapeutics, Inc. are of similar size ($1.6B and $1.5B). Immunocore Holdings PLC Sponsored ADR grew revenue faster over the last twelve months: 21.0% against 12.6%. Immunocore Holdings PLC Sponsored ADR has the higher net margin (−4.20% vs −672.2%) and the higher return on invested capital (0.00% vs −91.3%). Across the 18 metrics below, Immunocore Holdings PLC Sponsored ADR leads on 13 and Intellia Therapeutics, Inc. on 5.

Valuation

Metric IMCR NTLA Biotechnology median
P/E n/m n/m 8.50
P/S 3.48 25.62 9.71
P/B 3.57 2.09 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 2.46 18.26 9.21
Earnings yield (1.22%) (29.42%) (33.15%)
Free cash flow yield (2.75%) (22.87%) (25.50%)

Profitability

Metric IMCR NTLA Biotechnology median
Gross margin 98.90% 100.00% 65.16%
Operating margin (5.24%) (711.66%) 0.00%
Net margin (4.20%) (672.16%) 0.00%
Free cash flow margin (9.55%) (585.82%) 0.00%
Return on equity (4.47%) (55.44%) (56.36%)
Return on assets (1.64%) (45.55%) (48.04%)
Return on invested capital 0.00% (91.28%) 0.00%

Growth

Metric IMCR NTLA Biotechnology median
Revenue growth (TTM) 20.95% 12.58% 6.02%
EPS growth (last fiscal year) 30.39% 27.43% 30.26%
Revenue growth, 5-year CAGR 59.57% 3.13% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IMCR NTLA Biotechnology median
Debt to equity 0.94 0.00 0.00
Current ratio 4.47 6.65 4.72
Net debt to EBITDA 11.19 1.06 0.96

Dividend

Metric IMCR NTLA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IMCR NTLA Biotechnology median
Market cap 1.52b 1.59b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack